Researchers in Austria investigated whether the time interval from surgery to start of chemotherapy has an impact on clinical outcome in patients with advanced serous ovarian cancer… Read on
Dr. Coleman, a member of the Alliance’s Scientific and Medical Advisory Board, conducted an interview on ovarian cancer therapies for the Cancer Network… Read on
Research published online last week in Nature Communications suggests that some of the cell lines most frequently used to study high-grade serous ovarian cancer (HGSOC) may not be the best… Read on
In an article published last week in The Lancet, an international group of investigators examined whether ovarian cancer tumors’ expression of the progesterone receptor (PR) and estrogen receptor (ER) was associated with survival in various… Read on
Women with a family history of breast cancer but no BRCA1/2 mutation were found to be at average risk for developing ovarian cancer… Read on
In an interview, 3-time grantee Dr. Zhang discusses his research and what it means to receive an award from OCRF… Read on
We recently returned from the annual meeting of the American Society of Clinical Oncology (ASCO), an annual event that gathers thousands of cancer researchers from around the world… Read on
In a unanimous ruling issued June 13, 2013, the US Supreme Court ruled that private companies do not have the right to patent human genes. In Association for Molecular Pathology et al. v… Read on
Society for Nuclear Medicine and Molecular Imaging (SNMMI) Advocate Report from Laurel Pracht As a member of the SNMMI Advocate Advisory Board, formed in 2010 to better bridge the gap between the patient and nuclear medicine communities, I represent… Read on
Ruling Will Give Women More Options to Learn About Genetic Risk Washington, DC—The Supreme Court ruled today that a company cannot patent naturally occurring genes, including isolated gene segments, overturning a decision made by the United States… Read on
